• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of diabetes investigation. >Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial
【24h】

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial

机译：与初诊利格列汀相比口服利那列汀和二甲双胍降低血糖作为亚洲初诊新发2型糖尿病和高血糖症患者的初始治疗：一项随机临床试验的亚组分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims/Introduction Type 2 diabetes mellitus is an epidemic in Asia, yet clinical trials of glucose‐lowering therapies often enroll predominantly Western populations. We explored the initial combination of metformin and linagliptin, a dipeptidyl peptidase‐4 inhibitor, in newly diagnosed type 2 diabetes mellitus patients in Asia with marked hyperglycemia. Materials and Methods This was a post‐hoc subgroup analysis of a multinational, parallel‐group clinical trial in which 316 newly diagnosed type 2 diabetes mellitus patients with glycated hemoglobin A1c (HbA1c) 8.5–12.0% were randomized to double‐blind oral treatment with linagliptin/metformin or linagliptin monotherapy. The primary end‐point was the change from baseline in HbA1c at week 24. We evaluated data for the 125 participants from Asian countries. Results After 24 weeks, the mean ± standard error reduction from baseline in HbA1c (mean 10.0%) was ?2.99 ± 0.18% with linagliptin/metformin and ?1.84 ± 0.18% with linagliptin; a treatment difference of ?1.15% (95% confidence interval ?1.65 to ?0.66, P Conclusions In people from Asia with newly diagnosed type 2 diabetes mellitus and marked hyperglycemia, the initial combination of linagliptin and metformin substantially improved glycemic control without weight gain and with infrequent hypoglycemia. Initial oral combination therapy might be a viable treatment for such individuals.
机译：目的/简介2型糖尿病在亚洲是一种流行病，但降糖疗法的临床试验通常主要招募西方人群。我们在亚洲地区新诊断出的伴有高血糖症的2型糖尿病患者中探索了二甲双胍和利格列汀（一种二肽基肽酶-4抑制剂）的初始组合。材料和方法这是一项多国平行临床试验的事后亚组分析，该研究将316名新诊断为糖化血红蛋白A1c（HbA1c）8.5–12.0％的2型糖尿病患者随机分为两组，分别接受双盲口服治疗利格列汀/二甲双胍或利格列汀单药治疗。主要终点是第24周时HbA1c相对基线的变化。我们评估了来自亚洲国家的125名参与者的数据。结果24周后，利格列汀/二甲双胍对HbA1c的平均±标准误差降低（平均10.0％），约为2.99±0.18％，而利格列汀为1.84±0.18％。治疗差异为1.15％（95％置信区间为1.65到0.66，P）结论在亚洲新诊断的2型糖尿病和高血糖症患者中，利格列汀和二甲双胍的初始组合可显着改善血糖控制，且无体重增加和对于低血糖的患者，最初的口服联合疗法可能是这类患者的可行治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号